Read by QxMD icon Read

Esophagogastric junction adenocarcinoma

Tomoki Shimizu, Junko Fujisaki, Masami Omae, Akira Yamasaki, Yusuke Horiuchi, Akiyoshi Ishiyama, Toshiyuki Yoshio, Toshiaki Hirasawa, Yorimasa Yamamoto, Tomohiro Tsuchida
BACKGROUND: In recent years, effective outcomes of endoscopic submucosal dissection (ESD) for esophagogastric junction cancer including short-segment Barrett's esophagus (SSBE) cancer have been reported. However, the efficacy of ESD for long-segment Barrett's esophagus (LSBE) cancer is unknown. AIM: To clarify the treatment outcomes of ESD for LSBE cancer versus SSBE cancer. METHODS: A total of 86 patients with 91 superficial Barrett's esophageal adenocarcinomas who underwent ESD were enrolled; of these, 68 had underlying SSBE and 18 had LSBE...
March 14, 2018: Digestion
Rodica Birla, Petre Hoara, Andrei Caragui, Marica Cristian, Silviu Constantinoiu
Adenocarcinoma of the gastroesophageal junction is more common in the West. Preoperative chemotherapy or chemoradiotherapy is performed for locally advanced disease. Recent studies are suggesting higher rates of curative resection and reduced rates of local recurrence in patients with neoadjuvant combination of chemotherapy and radiation therapy. The role of targeted agents in neoadjuvant therapy is under investigation.
January 2018: Chirurgia
Gerd Jomrich, Marlene Hollenstein, Maximilian John, Andreas Baierl, Matthias Paireder, Ivan Kristo, Aysegül Ilhan-Mutlu, Reza Asari, Matthias Preusser, Sebastian F Schoppmann
The modified Glasgow Prognostic Score (mGPS) combines the indicators of decreased plasma albumin and elevated CRP. In a number of malignancies, elevated mGPS is associated with poor survival. Aim of this study was to investigate the prognostic role of mGPS in patients with neoadjuvantly treated adenocarcinomas of the esophagogastric junction 256 patients from a prospective database undergoing surgical resection after neoadjuvant treatment between 2003 and 2014 were evaluated. mGPS was scored as 0, 1, or 2 based on CRP (>1...
January 23, 2018: Oncotarget
Kazuyuki Tanaka, Mikihiro Fujiya, Masami Ijiri, Keitaro Takahashi, Katsuyoshi Ando, Yoshiki Nomura, Nobuhiro Ueno, Shin Kashima, Takuma Goto, Junpei Sasajima, Takahiro Ito, Kentaro Moriichi, Yusuke Mizukami, Hiroki Tanabe, Toshikatsu Okumura
No abstract text is available yet for this article.
February 19, 2018: Journal of Gastrointestinal Cancer
Yingcai Hong, Huaisheng Chen, Zhanpeng Rao, Bin Peng, Hong Hu, Shaolin Lin, Zhenglei Xu
Trastuzumab is recommended for the treatment of human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagogastric junction (AEG) in combination with chemotherapy; however, drug resistance has severely affected its clinical application. The present study aimed to investigate the effect of sex determining region Y-box 9 (SOX9), a prognostic marker in adjuvant oncological settings, on AEG cell proliferation and apoptosis in the presence or absence of trastuzumab. Furthermore, the molecular mechanism underlying the role of SOX9 in trastuzumab resistance was explored...
March 2018: Experimental and Therapeutic Medicine
Hyun Ju Kim, Hyunsoo Chung, Sung Kwan Shin, Hyoung-Il Kim, Jun Chul Park, Sang Kil Lee, Woo Jin Hyung, Yong Chan Lee, Sung Hoon Noh
BACKGROUND: The aim of this study was to analyze long-term clinical and oncologic outcomes in patients with early-stage adenocarcinoma of the esophagogastric junction (AEG) managed with either endoscopic resection (ER) or surgery. METHODS: The inclusion criteria were AEG, meeting classic or expanded indications for ER of early gastric cancer, and complete resection. A total of 66 patients with Siewert type II AEG were included (ER group, n = 38; vs. surgery group, n = 28)...
February 7, 2018: Surgical Endoscopy
Xueke Ge, Qun Zhao, Yuzhi Song, Jing Li, Ming Liu, Wenwen Bai, Xueying Qiao
PURPOSE: Preoperative therapy improves overall survival (OS) after surgery in patients with adenocarcinoma of the esophagogastric junction (AEG). We aimed to retrospectively analyze whether preoperative chemoradiotherapy (CRT) could improve the prognosis of patients with locally advanced Siewert II and III AEG comparing with preoperative chemotherapy alone (CT). PATIENTS AND METHODS: From March 2012 to December 2015, 170 patients with locally advanced (cT3-4NxM0) Siewert II and III AEG were treated with preoperative CRT or CT in Hebei Medical University Fourth Hospital, and 123 patients were included in this study to compare the effects of preoperative CRT with CT...
January 9, 2018: European Journal of Surgical Oncology
Yusuke Fujii, Noriyuki Hirahara, Shunsuke Kaji, Yoshiko Miyazaki, Takashi Kishi, Takahito Taniura, Ryoji Hyakudomi, Tetsu Yamamoto, Takeshi Nishi, Hikota Hayashi, Yasunari Kawabata, Yoshitsugu Tajima
A 60s-year-old Japanese male underwent curative resection for an advanced adenocarcinoma of the esophagogastric junction(Stage III C), followed by adjuvant chemotherapy.Twenty -one months later, he was admitted to our hospital with a complaint of marked decline in activities of daily living(ADL).The patient was diagnosed with pancytopenia, disseminated intravascular coagulation(DIC), multiple lymph node and bone metastases, and bone marrow carcinomatosis.After completing a sufficient informed consent process, he received chemotherapy along with blood transfusion, and then DIC, pancytopenia, and ADL of the patient improved...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Toshiki Hirakawa, Junya Morimoto, Kazunori Nakazawa, Hironari Miyamoto, Takuma Okada, Chihoko Nobori, Shigeaki Kurihara, En Wang, Naoki Aomatsu, Takehiko Iwauchi, Shigehito Yamagata, Yasutake Uchima, Kazuhiro Takeuchi
A 65-year-old man presented with severe strictures from the esophagogastric junction to the body of the stomach and was histopathologically diagnosed with adenocarcinoma. Computed tomography showed multiple peritoneal metastases. A long, covered metallic stent was placed, and chemotherapy was started. Subsequent granulation from the oral side of the stent caused stricture formation, and a covered stent was also placed. After 8 months, granulation from the oral side of the stent caused recurrent stricture formation...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Yuto Kitano, Jun Kinoshita, Katsunobu Oyama, Koichi Okamoto, Seisho Sakai, Isamu Makino, Keishi Nakamura, Hironori Hayashi, Masafumi Inokuchi, Tomoharu Miyashita, Hidehiro Tajima, Hiroyuki Takamura, Itasu Ninomiya, Sachio Fushida, Tetsuo Ohta
Gastric cancer rarely contains neuroendocrine component. This mixed tumor is defined as neuroendocrine carcinoma (NEC), mixed adenoneuroendocrine carcinoma(MANEC)and so on according to the WHO classification. We report a patient with esophagogastric junction cancer with neuroendocrine differentiation(NED). The patient was 54-year-old man who diagnosed of esophagogastric junction cancer at the medical examination. Upper gastrointestinal endoscopy revealed a type 3 tumor at esophagogastric junction, and the pathological findings were poorly differentiated adenocarcinoma with focal positivity of chromogranin A...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Yasuaki Nagami, Masaki Ominami, Koji Otani, Shuhei Hosomi, Fumio Tanaka, Koichi Taira, Noriko Kamata, Hirokazu Yamagami, Tetsuya Tanigawa, Masatsugu Shiba, Toshio Watanabe, Yasuhiro Fujiwara
BACKGROUND: Adenocarcinoma of the esophagogastric junction (EGJ) is uncommon in Eastern countries, including Japan, but it is believed that the incidence of EGJ adenocarcinoma will increase in Asia in the future due to the decreasing incidence of Helicobacter pylori infection. Endoscopic submucosal dissection (ESD) is a minimally invasive and curative treatment that allows precise pathological assessment. SUMMARY: Magnifying endoscopy with narrow-band imaging may be useful for differential diagnoses and for delineating the cancer margin of EGJ adenocarcinoma, but subsquamous carcinoma extension, which is the invasion of EGJ adenocarcinoma beneath the normal esophageal squamous epithelium, makes it difficult to detect cancer margins of the oral side in ESD for EGJ adenocarcinoma...
February 1, 2018: Digestion
Guowen Ding, Yafeng Wang, Yu Chen, Jun Yin, Chao Liu, Yu Fan, Hao Qiu, Weifeng Tang, Shuchen Chen
In this study, we aimed to determine the potential association of MTHFR tagging single nucleotide polymorphisms (SNPs) with risk of developing esophagogastric junction adenocarcinoma (EGJA). MTHFR rs1801133 G>A, rs3753584 T>C, rs4845882 G>A, rs4846048 A>G and rs9651118 T>C polymorphisms were genotyped in 1,677 healthy individuals and 1,063 patients with EGJA. We found that MTHFR rs1801133 G>A polymorphism was significantly associated with the risk of developing EGJA (AA vs. GG: adjusted P = 0...
December 19, 2017: Oncotarget
Zhangjian Zhou, Xin Xie, Nan Hao, Dongmei Diao, Yongchun Song, Peng Xia, Chengxue Dang, Hao Zhang
OBJECTIVE: In addition to the traditional TNM N staging system, lymph node ratio (LNR) and log odds of metastatic lymph nodes (LODDS) staging methods were developed in cancers. We aimed to examine their relative prognostic performance in patients with adenocarcinoma of esophagogastric junction (AEG). PATIENTS AND METHODS: Patients who underwent surgical resection for AEG were identified from the Surveillance, Epidemiology, and End Results (SEER) Program and the First Affiliated Hospital of Xi'an Jiaotong University as the training and validation sets, respectively...
January 17, 2018: Current Medical Research and Opinion
Harald Schmalenberg, Salah-Eddin Al-Batran, Claudia Pauligk, Thomas Zander, Alexander Reichart, Udo Lindig, Mathias Kleiß, Lothar Müller, Claus Bolling, Thomas Seufferlein, Peter Reichardt, Frank Kullmann, Henning Eschenburg, Alexander Schmittel, Matthias Egger, Andreas Block, Thorsten Oliver Goetze
INTRODUCTION: This is a single-arm study (NCT01956149) to determine the prolonged (≥ 4 months) disease control rate with cabazitaxel administered in second-(or later) setting for patients with advanced or metastatic adenocarcinoma of the esophagogastric junction (EGJ) and stomach. METHODS: 65 patients with advanced EGJ and stomach cancer were treated with 20 mg/m2 cabazitaxel every 3 weeks for a maximum of six cycles. The main objective of the study is a prolonged disease control rate (pDCR: CR, PR or SD lasting at least 4 months)...
December 28, 2017: Journal of Cancer Research and Clinical Oncology
Salah-Eddin Al-Batran, Thorsten O Goetze, Daniel W Mueller, Arndt Vogel, Michael Winkler, Sylvie Lorenzen, Alexander Novotny, Claudia Pauligk, Nils Homann, Thomas Jungbluth, Christoph Reissfelder, Karel Caca, Steffen Retter, Eva Horndasch, Julia Gumpp, Claus Bolling, Karl-Hermann Fuchs, Wolfgang Blau, Winfried Padberg, Michael Pohl, Andreas Wunsch, Patrick Michl, Frank Mannes, Matthias Schwarzbach, Harald Schmalenberg, Michael Hohaus, Christian Scholz, Christoph Benckert, Jorge Riera Knorrenschild, Veit Kanngießer, Thomas Zander, Hakan Alakus, Ralf-Dieter Hofheinz, Claus Roedel, Manish A Shah, Mitsuru Sasako, Dietmar Lorenz, Jakob Izbicki, Wolf O Bechstein, Hauke Lang, Stefan P Moenig
BACKGROUND: Historical data indicate that surgical resection may benefit select patients with metastatic gastric and gastroesophageal junction cancer. However, randomized clinical trials are lacking. The current RENAISSANCE trial addresses the potential benefits of surgical intervention in gastric and gastroesophageal junction cancer with limited metastases. METHODS: This is a prospective, multicenter, randomized, investigator-initiated phase III trial. Previously untreated patients with limited metastatic stage (retroperitoneal lymph node metastases only or a maximum of one incurable organ site that is potentially resectable or locally controllable with or without retroperitoneal lymph nodes) receive 4 cycles of FLOT chemotherapy alone or with trastuzumab if Her2+...
December 28, 2017: BMC Cancer
Sung Don Oh, Sung Jin Oh, Byoung Jo Suh, Jin Yong Shin, Jong Kwon Park
Portal vein tumor thrombosis (PVTT) with advanced gastric cancer is very rare; when it occurs, it exhibits aggressive growth and carries a poor prognosis. In addition, definitive treatment has not been established due to insufficient data. Herein, we report a case of PVTT associated with an adenocarcinoma of the esophagogastric junction that was successfully controlled by means of a palliative total gastrectomy without surgical resection of the PVTT and administration of palliative continuous doxifluridine.
September 2017: Case Reports in Oncology
Kunio Mochizuki, Tetsuo Kondo, Naoki Oishi, Ippei Tahara, Tomohiro Inoue, Kazunari Kasai, Tadao Nakazawa, Ryohei Katoh
BACKGROUND/AIM: Although differentiating squamous cell carcinoma (SCC) from adenocarcinoma (AC) at the esophagogastric junction (EGJ) is important for the choice of treatment, this can occasionally be difficult with small biopsy specimens. Therefore, the purpose of this study was to determine the most useful immunomarker panel for discriminating between SCC and AC of the EGJ. MATERIALS AND METHODS: We analyzed 15 SCCs and 26 ACs of the EGJ obtained surgically using immunohistochemistry...
December 2017: Anticancer Research
Christoph Treese, Hannah Harloff, Severin Daum
No abstract text is available yet for this article.
September 2017: Zeitschrift Für Gastroenterologie
Miao-Zhen Qiu, Si-Mei Shi, Min Chen, Jing Wang, Qi-Nian Wu, Hui Sheng, Hui-Zhong Zhang, Jing-Ping Yun, Zhi-Wei Zhou, Feng-Hua Wang, Da-Jun Yang, Rui-Hua Xu
Purpose: Patients with advanced or metastatic adenocarcinoma of the stomach or esophagogastric junction for whom trastuzumab therapy is being considered, assessment for tumor human epidermal growth factor receptor-2 (HER2) status is necessary. Can the HER2 status and Lauren classification of the biopsy sample truly represent the HER2 status in the gastric cancer? Methods: Formalin-fixed, paraffin-embedded sections of 116 pair surgically resected and biopsy specimens as well as 80 pair primary and metastatic lesions of gastric cancer patients were analyzed...
2017: Journal of Cancer
Kenichi Aratani, Shuhei Komatsu, Daisuke Ichikawa, Takuma Ohashi, Mahito Miyamae, Wataru Okajima, Taisuke Imamura, Jun Kiuchi, Keiji Nishibeppu, Toshiyuki Kosuga, Hirotaka Konishi, Atsushi Shiozaki, Hitoshi Fujiwara, Kazuma Okamoto, Hitoshi Tsuda, Eigo Otsuji
Background: To detect a novel treatment target for adenocarcinoma of the esophagogastric junction (AEG), we tested whether C-terminal tensin-like (CTEN), a member of the tensin gene family and frequently overexpressed in various cancers, acts as a cancer-promoting gene through overexpression in AEG. Materials and Methods: We analyzed 5 gastric adenocarcinoma (GC) cell lines and 104 primary AEG tumors curatively resected in our hospital between 2000 and 2010. Results: CTEN overexpression was detected in GC cell lines (2/5 cell lines; 40%) and primary AEG tumor samples (35/104 cases; 34%)...
October 13, 2017: Oncotarget
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"